ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > PMN-267

<< Previous

Bullboard Posts

Next >>

Comment by M101on Apr 29, 2022 12:50pm

140 Views

Post# 34642774

RE:RE:RE:PMN-267

bball67 wrote: I don't recall Promis devoting a PR solely to ALS.

I don't recall one either, which is why I think they could do a better job promoting this progress.
I don't care which CNS disease is used to validate the platform and central hypothesis, but I would have chosen the quickest path before the biggest market and ALS could still end up providing that path.

<< Previous

Bullboard Posts

Next >>

The top 10 Canadian medical stocks